Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-74699157 in Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT04006301Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of JNJ-74699157 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of Participants with Dose-Limiting Toxicity up to 2 years, Number of Participants with Adverse Events up to 4 years and 2 more. Started Jul 2019; status: completed.
02
Drugs
JNJ-74699157
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04006301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04006301.